Biofrontera【BFRI】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

1.1201

買値

1.12

売値

1.17

出来高

217,670

1.11 日の範囲 1.19

0.647 52 週間の範囲 2.4302

時価総額

8.68M

前日終値

1.17

始値

1.19

時刻

1.17

最終取引時間

財務取引量

US$ 252,629

VWAP

1.1606

平均取引量 (3 か月)

911,099

発行済株式数

7,749,211

配当利回り

PER

-0.45

1 株当たり利益 (EPS)

-2.6

歳入

34.07M

純利益

-20.13M

Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic kerat... Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer. It also markets a topical antibiotic for the treatment of impetigo, a bacterial skin infection. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.biofrontera-us.com

本社

Dover, Delaware, USA

設立

Biofrontera Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker BFRI. The last closing price for Biofrontera was US$1.17. Over the last year, Biofrontera shares have traded in a share price range of US$ 0.647 to US$ 2.4302.

Biofrontera currently has 7,749,211 shares in issue. The market capitalisation of Biofrontera is US$9.07 million. Biofrontera has a price to earnings ratio (PE ratio) of -0.45.

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be...

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US...

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the...

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue...

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly...

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete...

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0499	-4.26495726496	1.17	1.1899	1.06	128975	1.12909494	CS
4	0.0301	2.76146788991	1.09	1.2399	1	173243	1.10750455	CS
12	0.3381	43.2352941176	0.782	1.87	0.7777	911099	1.06212236	CS
26	-0.1599	-12.4921875	1.28	2.22	0.651266	1732026	1.16179792	CS
52	0.4201	60.0142857143	0.7	2.4302	0.647	1035419	1.16731621	CS
156	-66.0799	-98.3331845238	67.2	122.4	0.61	638112	26.16025603	CS
260	-80.6799	-98.6306845966	81.8	292.6	0.61	1968455	105.08361971	CS

BFRI - Frequently Asked Questions (FAQ)

What is the current Biofrontera share price?

The current share price of Biofrontera is US$ 1.1201

How many Biofrontera shares are in issue?

Biofrontera has 7,749,211 shares in issue

What is the market cap of Biofrontera?

The market capitalisation of Biofrontera is USD 9.07M

What is the 1 year trading range for Biofrontera share price?

Biofrontera has traded in the range of US$ 0.647 to US$ 2.4302 during the past year

What is the PE ratio of Biofrontera?

The price to earnings ratio of Biofrontera is -0.45

What is the cash to sales ratio of Biofrontera?

The cash to sales ratio of Biofrontera is 0.27

What is the reporting currency for Biofrontera?

Biofrontera reports financial results in USD

What is the latest annual turnover for Biofrontera?

The latest annual turnover of Biofrontera is USD 34.07M

What is the latest annual profit for Biofrontera?

The latest annual profit of Biofrontera is USD -20.13M

What is the registered address of Biofrontera?

The registered address for Biofrontera is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904

What is the Biofrontera website address?

The website address for Biofrontera is www.biofrontera-us.com

Which industry sector does Biofrontera operate in?

Biofrontera operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
JTAIJet AI Inc	US$ 6.02 (133.33%)	101.64M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	248.48M
WRDWeRide Inc	US$ 31.4877 (83.39%)	20.57M
INLFINLIF Limited	US$ 16.27 (80.58%)	7.67M
MBRXMoleculin Biotech Inc	US$ 2.1201 (66.94%)	134.88M
BLACBellevue Life Sciences Acquisition Corporation	US$ 3.08 (-56.31%)	425.19k
BLACUBellevue Life Sciences Acquisition Corporation	US$ 3.36 (-52.68%)	5.21k
CSAICloudastructure Inc	US$ 19.0001 (-49.58%)	1.01M
NEXNNexxen International Ltd	US$ 10.30 (-49.16%)	160.99k
BSLKBolt Projects Holdings Inc	US$ 0.6626 (-46.13%)	13.07M
CNSPCNS Pharmaceuticals Inc	US$ 0.1415 (31.26%)	489.28M
MGOLMGO Global Inc	US$ 0.7176 (-15.08%)	417.31M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	254.39M
INTCIntel Corporation	US$ 23.60 (-2.20%)	230.26M
NVDANVIDIA Corporation	US$ 138.85 (2.63%)	194.99M

銘柄コード

株価

出来高